Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uma Sinha

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
Circulation|November 18, 2024
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialDaniel P Judge, Julian D Gillmore, Kevin M Alexander, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitorPenglie Zhang, Wenrong Huang, Lingyan Wang, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
Circulation|November 18, 2024
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM TrialDaniel P Judge, Julian D Gillmore, Kevin M Alexander, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitorPenglie Zhang, Wenrong Huang, Lingyan Wang, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
Pageof 8